Access shifts: shortages ease
Access to GLP‑1 drugs is changing fast — the FDA removed GLP‑1s from its drug‑shortage list (so compounding exceptions end) while Eli Lilly and Walmart expanded direct‑to‑consumer access and nationwide pharmacy pickup for tirzepatide (Zepbound). That combination reduces shortage pressure but also raises questions about how people will source these medications and whether easier access will increase demand and safety concerns. (drugtopics.com) (drugtopics.com) (fox61.com).
A year ago, people hunting for weight-loss shots were bouncing between pharmacies, telehealth sites, and compounders. Now the United States Food and Drug Administration says the shortages for tirzepatide and semaglutide are resolved, which shuts off the main shortcut that let many pharmacies make copycat versions during the crunch. (fda.gov) (content.govdelivery.com) Tirzepatide is the ingredient in Eli Lilly’s Zepbound for obesity and Mounjaro for diabetes. The Food and Drug Administration re-confirmed on December 19, 2024 that tirzepatide supply was no longer in shortage, and on February 21, 2025 it said the same for semaglutide injections. (wsgr.com) (content.govdelivery.com) That shortage status mattered because compounding is the pharmacy version of custom mixing, and the rules loosen when an approved drug is genuinely unavailable. Once the approved product is commercially available again, a compounded version that is basically the same drug in the same strength and same route can be treated as an illegal copy. (fda.gov) The Food and Drug Administration gave compounders a runway instead of a cliff. For semaglutide, state-licensed compounders got until April 22, 2025 and outsourcing facilities got until May 22, 2025 before the agency said it could resume enforcement tied to shortage status. (content.govdelivery.com) Then the market moved in the opposite direction on convenience. On October 29, 2025, Eli Lilly and Walmart said Zepbound single-dose vials ordered through LillyDirect could be picked up at Walmart pharmacies nationwide, with rollout targeted for mid-November. (corporate.walmart.com) (drugtopics.com) That changed the path from “find a hard-to-get drug” to “fill a prescription at a familiar counter.” Walmart said it has nearly 4,600 pharmacies nationwide, and Lilly said the pickup option was the first retail pharmacy link for LillyDirect’s self-pay Zepbound vials. (corporate.walmart.com) Price is part of the shift too. Drug Topics reported Lilly’s 2025 self-pay vial program listed 2.5 milligrams at $349 a month and 5, 7.5, 10, 12.5, and 15 milligrams at $499 a month through the direct program, while Walmart said its pickup pricing would match LillyDirect for approved strengths. (drugtopics.com) (corporate.walmart.com) So the squeeze is easing in one place and tightening in another. Fewer people should need compounded stand-ins if branded supply is steadier and pickup is easier, but people who got used to telehealth-plus-compounding may now have to switch back to approved branded products or stop treatment. (fda.gov) (drugtopics.com) The safety fight is not over just because shelves look better. In September 2025, the Food and Drug Administration sent more than 50 warning letters to companies marketing compounded or unapproved glucagon-like peptide 1 drugs, including semaglutide and tirzepatide, over claims the agency said were false or misleading. (wsgr.com) (fda.gov) That leaves patients with a new map. The emergency era of “get it anywhere you can” is fading, and the replacement looks more like regular pharmacy distribution: approved drug, branded supply, fixed prices, and a lot less room for gray-market substitutes. (fda.gov) (corporate.walmart.com)
